Bicara Therapeutics Inc.
corporate_fare Company Profile
Bicara Therapeutics Inc. (NASDAQ:BCAX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for BCAX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for BCAX spans 8-K, 10-Q, 144, 10-K.
Recent high-impact activity:
- Bicara Q3 Loss Widens to $71.2M; $442.3M Cash Funds Operations Into 1H 2029
- Bicara Q2 2026: Cash Runway Extended to 2029, CEO Transition and CFO Change Detailed
- Bicara Delivers Q2 2026 Results, Reshapes Leadership, and Advances Pivotal Trial
- Bicara Overhauls C-Suite, Names New CEO and CFO Ahead of Pivotal Data
- Former Chief Legal Officer Files Intent to Sell $1.47M in Shares Acquired via Options
Financial Snapshot
Short Interest & Short Volume
3.84 days to coverFINRA reported short interest of 9,861,807 shares in BCAX as of the October 30, 2026 settlement, a 4.2% decrease from the prior period — about 3.8 days to cover at its recent average daily volume. On November 20, 2026, 42.1% of BCAX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.